News Channels

14 Mar 2023 Exscientia Announces Expansion of its Precision Oncology Pipeline
14 Mar 2023 Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI)
14 Mar 2023 Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
14 Mar 2023 VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
14 Mar 2023 Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis
14 Mar 2023 Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial
13 Mar 2023 Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
13 Mar 2023 Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
13 Mar 2023 Pfizer Invests $43 Billion to Battle Cancer
13 Mar 2023 ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
13 Mar 2023 GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial
13 Mar 2023 Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 as a Potential Treatment for Duchenne Muscular Dystrophy
11 Mar 2023 Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
11 Mar 2023 Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
10 Mar 2023 KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
10 Mar 2023 Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4
10 Mar 2023 AusperBio Announces First-in-Human Dosing of AHB-137, an Antisense Oligonucleotide Drug Candidate for the Treatment of Chronic Hepatitis B
10 Mar 2023 Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study with RBN-3143 in Patients with Moderate-to-Severe Atopic Dermatitis
10 Mar 2023 InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
10 Mar 2023 Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up